Share-based Payment Arrangement, Expense of Vir Biotechnology, Inc. from 31 Dec 2017 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Vir Biotechnology, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2017 to 30 Sep 2025.
  • Vir Biotechnology, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $11,356,000, a 32% decline year-over-year.
  • Vir Biotechnology, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $53,707,000, a 41% decline year-over-year.
  • Vir Biotechnology, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $78,457,000, a 30% decline from 2023.
  • Vir Biotechnology, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $111,316,000, a 9% increase from 2022.
  • Vir Biotechnology, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $102,082,000, a 22% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Vir Biotechnology, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $53,707,000 $11,356,000 -$5,341,000 -32% 01 Jul 2025 30 Sep 2025 10-Q 05 Nov 2025 2025 Q3
Q2 2025 $59,048,000 $12,451,000 -$9,711,000 -44% 01 Apr 2025 30 Jun 2025 10-Q 06 Aug 2025 2025 Q2
Q1 2025 $68,759,000 $14,059,000 -$9,698,000 -41% 01 Jan 2025 31 Mar 2025 10-Q 08 May 2025 2025 Q1
Q4 2024 $78,457,000 $15,841,000 -$12,431,000 -44% 01 Oct 2024 31 Dec 2024 10-K 27 Feb 2025 2024 FY
Q3 2024 $90,888,000 $16,697,000 -$10,247,000 -38% 01 Jul 2024 30 Sep 2024 10-Q 05 Nov 2025 2025 Q3
Q2 2024 $101,135,000 $22,162,000 -$8,457,000 -28% 01 Apr 2024 30 Jun 2024 10-Q 06 Aug 2025 2025 Q2
Q1 2024 $109,592,000 $23,757,000 -$1,724,000 -6.8% 01 Jan 2024 31 Mar 2024 10-Q 08 May 2025 2025 Q1
Q4 2023 $111,316,000 $28,272,000 +$3,407,000 +14% 01 Oct 2023 31 Dec 2023 10-K 27 Feb 2025 2024 FY
Q3 2023 $107,909,000 $26,944,000 +$2,130,000 +8.6% 01 Jul 2023 30 Sep 2023 10-Q 04 Nov 2024 2024 Q3
Q2 2023 $105,779,000 $30,619,000 +$3,520,000 +13% 01 Apr 2023 30 Jun 2023 10-Q 01 Aug 2024 2024 Q2
Q1 2023 $102,259,000 $25,481,000 +$177,000 +0.7% 01 Jan 2023 31 Mar 2023 10-Q 03 May 2024 2024 Q1
Q4 2022 $102,082,000 $24,865,000 +$494,000 +2% 01 Oct 2022 31 Dec 2022 10-K 27 Feb 2025 2024 FY
Q3 2022 $101,588,000 $24,814,000 +$1,870,000 +8.2% 01 Jul 2022 30 Sep 2022 10-Q 03 Nov 2023 2023 Q3
Q2 2022 $99,718,000 $27,099,000 +$6,101,000 +29% 01 Apr 2022 30 Jun 2022 10-Q 04 Aug 2023 2023 Q2
Q1 2022 $93,617,000 $25,304,000 +$9,833,000 +64% 01 Jan 2022 31 Mar 2022 10-Q 08 May 2023 2023 Q1
Q4 2021 $83,784,000 $24,371,000 +$14,070,000 +137% 01 Oct 2021 31 Dec 2021 10-K 26 Feb 2024 2023 FY
Q3 2021 $69,714,000 $22,944,000 +$14,362,000 +167% 01 Jul 2021 30 Sep 2021 10-Q 03 Nov 2022 2022 Q3
Q2 2021 $55,352,000 $20,998,000 +$15,248,000 +265% 01 Apr 2021 30 Jun 2021 10-Q 09 Aug 2022 2022 Q2
Q1 2021 $40,104,000 $15,471,000 +$12,504,000 +421% 01 Jan 2021 31 Mar 2021 10-Q 05 May 2022 2022 Q1
Q4 2020 $27,600,000 $10,301,000 +$7,622,000 +285% 01 Oct 2020 31 Dec 2020 10-K 28 Feb 2023 2022 FY
Q3 2020 $19,978,000 $8,582,000 +$6,394,000 +292% 01 Jul 2020 30 Sep 2020 10-Q 04 Nov 2021 2021 Q3
Q2 2020 $13,584,000 $5,750,000 +$4,351,000 +311% 01 Apr 2020 30 Jun 2020 10-Q 05 Aug 2021 2021 Q2
Q1 2020 $9,233,000 $2,967,000 +$514,000 +21% 01 Jan 2020 31 Mar 2020 10-Q 06 May 2021 2021 Q1
Q4 2019 $8,719,000 $2,679,000 01 Oct 2019 31 Dec 2019 10-K 28 Feb 2022 2021 FY
Q3 2019 $2,188,000 +$739,000 +51% 01 Jul 2019 30 Sep 2019 10-Q 10 Nov 2020 2020 Q3
Q2 2019 $1,399,000 01 Apr 2019 30 Jun 2019 10-Q 11 Aug 2020 2020 Q2
Q1 2019 $2,453,000 01 Jan 2019 31 Mar 2019 10-Q 12 May 2020 2020 Q1
Q3 2018 $1,449,000 01 Jul 2018 30 Sep 2018 10-Q 19 Nov 2019 2019 Q3

Vir Biotechnology, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $78,457,000 -$32,859,000 -30% 01 Jan 2024 31 Dec 2024 10-K 27 Feb 2025 2024 FY
2023 $111,316,000 +$9,234,000 +9% 01 Jan 2023 31 Dec 2023 10-K 27 Feb 2025 2024 FY
2022 $102,082,000 +$18,298,000 +22% 01 Jan 2022 31 Dec 2022 10-K 27 Feb 2025 2024 FY
2021 $83,784,000 +$56,184,000 +204% 01 Jan 2021 31 Dec 2021 10-K 26 Feb 2024 2023 FY
2020 $27,600,000 +$18,881,000 +217% 01 Jan 2020 31 Dec 2020 10-K 28 Feb 2023 2022 FY
2019 $8,719,000 +$3,666,000 +73% 01 Jan 2019 31 Dec 2019 10-K 28 Feb 2022 2021 FY
2018 $5,053,000 +$271,000 +5.7% 01 Jan 2018 31 Dec 2018 10-K 25 Feb 2021 2020 FY
2017 $4,782,000 01 Jan 2017 31 Dec 2017 10-K 26 Mar 2020 2019 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.